NDA 021355 · Bayer Hlthcare
Angeliq
Drospirenone, Estradiol · Oral · Progestin; Estrogen
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Sep 28, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
146
48 Phase 3, 7 recruiting
FAERS reports
540
312 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ]. The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5...
What it is approved for
From the label in effect Mar 2, 2026.
Use estrogen, alone or in combination with a progestogen, at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman. Re-evaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary. Angeliq is a combination of an estrogen and progestin indicated in a woman with a uterus for the treatment of: Moderate to severe vasomotor symptoms due to menopause. ( 1.1 ) Moderate to severe vulvar and vaginal atrophy symptoms due to menopause. ( 1.2 ) Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Angeliq 0.25 mg drospirenone (DRSP)/0.5 mg estradiol (E2) is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause in a woman with a uterus. Angeliq 0.5 mg DRSP/1 mg E2 is indicated for the treatment of moderate to severe vasomotor symptoms associated due to menopause in a woman with a uterus. 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Angeliq 0.5 mg DRSP/1 mg E2 is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause in a woman with a uterus.
Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol (E2) is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 29, 2012 Supplement 3 · Efficacy LetterLabel
- Sep 28, 2005 Original approval · Type 4 - New Combination LabelReviewLetter
2 products under this application
- ANGELIQ · DROSPIRENONE 0.5MG; ESTRADIOL 1MG · TABLET, ORAL · Prescription · TE AB
- ANGELIQ · DROSPIRENONE 0.25MG; ESTRADIOL 0.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00413062 · 2,281 participants · Start Jun 2006 · Primary completion Aug 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00511199 · 2,152 participants · Start May 1, 2006 · Primary completion Apr 1, 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada StudyPivotal-lookingCompleted
EstetraIndustry
NCT02817841 · 2,148 participants · Start Aug 30, 2016 · Primary completion Oct 16, 2018
Drug: 15 mg E4/3 mg DRSP · For: Contraception
Sites: Philadelphia, Pennsylvania; Québec, Canada
- YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in ChinaCompleted
BayerBayer (BAYRY)
NCT02710708 · 1,921 participants · Start May 27, 2016 · Primary completion Jul 3, 2018
Drug: EE20/DRSP (YAZ, BAY86-5300) · For: Contraception
Sites: Xiamen, China; Guangzhou, China; Shenzhen, China · 38 sites in all
- Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00567164 · 1,887 participants · Start Oct 2007 · Primary completion Nov 2009
Drug: EE20/DRSP (BAY86-5300); EE20/DRSP (BAY86-5300) and 1 more · For: Contraception; Ovulation Inhibition; Contraceptives, Oral
Sites: Montgomery, Alabama; Chandler, Arizona; Mesa, Arizona · 85 sites in all
- E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia StudyPivotal-lookingCompleted
EstetraIndustry
NCT02817828 · 1,577 participants · Start Jun 2016 · Primary completion Apr 26, 2018
Drug: 15 mg E4/3 mg DRSP · For: Contraception
Sites: Brussels, Belgium
- Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 CyclesPivotal-lookingCompleted
Laboratories Leon Farma, S.A.Industry
NCT02269241 · 1,552 participants · Start Oct 9, 2014 · Primary completion Oct 4, 2017
Drug: LF111 (drospirenone) · For: Contraception
Sites: Birmingham, Alabama; Anaheim, California; Costa Mesa, California · 37 sites in all
- Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in FemalesPivotal-lookingCompleted
Insud PharmaIndustry
NCT05461573 · 1,542 participants · Start Aug 2, 2022 · Primary completion Aug 5, 2024
Drug: Drospirenone · For: Contraception; Change in Bone Mineral Density
Sites: Alabaster, Alabama; Birmingham, Alabama; Tucson, Arizona · 47 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache31
- vaginal haemorrhage30
- hot flush26
- fatigue25
- drug ineffective24
- nausea24
- dizziness23
- metrorrhagia23
- alopecia22
- anxiety22
- malaise22
- abdominal pain21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 89 |
| 2009 | 54 |
| 2010 | 16 |
| 2011 | 47 |
| 2012 | 12 |
| 2013 | 29 |
| 2014 | 30 |
| 2015 | 11 |
| 2016 | 19 |
| 2017 | 17 |
| 2018 | 21 |
| 2019 | 21 |
| 2020 | 29 |
| 2021 | 16 |
| 2022 | 17 |
| 2023 | 15 |
| 2024 | 16 |
| 2025 | 60 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Angeliq (Drospirenone/Estradiol)
2024 spending
$404K
Beneficiaries
299
1,117 claims
Per beneficiary
$1,351
$6.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $343,107 |
| 2021 | $351,624 |
| 2022 | $393,367 |
| 2023 | $426,669 |
| 2024 | $404,049 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Hormonal contraception in women with endometriosis: a systematic review.
Grandi G, Barra F, Ferrero S, et al. · Eur J Contracept Reprod Health Care 2019 · Systematic Review
- Comparative effectiveness and safety of different progestins in combined oral contraceptives: a systematic review and network meta-analysis of randomized controlled trials.
Li B, Xu X, Xu K, et al. · Arch Gynecol Obstet 2025 · Comparative Study, Network Meta-Analysis
- Estetrol/Drospirenone safety in a population with cardiovascular risk factors.
Creinin MD, Foidart JM, Gemzell-Danielsson K, et al. · Contraception 2025 · Clinical Trial, Phase III
- Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Pkhaladze L, Russo M, Unfer V, et al. · Eur Rev Med Pharmacol Sci 2021 · Comparative Study, Randomized Controlled Trial
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, et al. · Int J Gynaecol Obstet 2018 · Meta-Analysis, Systematic Review
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.